New biomarkers in pain management; Clavis Pharma looks for AML biomarkers;

> New biomarkers in pain management may speed drug development and reduce costs. Item

> Norway's Clavis Pharma has received a $2.5 million grant from The Research Council of Norway to develop a hENT1 biomarker assay for targeted therapy of AML patients. Clavis release

> Immunological abnormalities are potential biomarkers in Chronic Fatigue Syndrome/ Myalgic Encephalomyelitis. Abstract

> In 2010, the total global market for biomarkers was an estimated $13.5 billion, according to a market report. Release

Suggested Articles

Coronavirus may not require a front-line battle yet in certain places, but it’s still taxing public health officials preparing for a potential crisis.

Cybernet Manufacturing, maker of medical-grade computer monitors, has unveiled a new, large touchscreen designed to protect against infections.

A startup has raised $12 million to fund its real-time system for monitoring patients undergoing dialysis at home and calling in complications.